Clinical pharmacology of atypical antipsychotics: An update

EXCLI Journal

Volumn 13, Issue , 2014, Pages 1163-1191

  Mauri, M C ^a   Paletta, S ^a   Maffini, M ^a   Colasanti, A ^b   Dragogna, F ^a   Di Pace, C ^a   Altamura, A C ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARIPRAZINE; CLOZAPINE; ILOPERIDONE; LURASIDONE; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ACUTE DISEASE; AREA UNDER THE CURVE; BEDTIME DOSAGE; BINDING AFFINITY; BINDING SITE; BIPOLAR DISORDER; CLINICAL EFFECTIVENESS; CLINICAL PHARMACOLOGY; COGNITIVE DEFECT; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; INSOMNIA; MAJOR DEPRESSION; MANIA; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; NAUSEA; NEGATIVE SYNDROME; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; POSITIVE SYNDROME; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; STEADY STATE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT GAIN;

EID: 84908007503     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell’Osso B, Mauri MC, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012;32:213-9.
2. Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998;31: 102-9.
3. Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. Intra- and interindividual variations in steadystate plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003;25:657-64.
4. Arif SA, Mitchell MM. Iloperidone: A new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68:301-8.
5. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233-46.
6. Attarbaschi T, Sacher J, Geiss-Granadia T, Klein N, Mossaheb N, Lanzenberger R, et al. Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol. 2007;17: 102-7.
7. Ballaz SJ, Akil H, Watson SJ. The 5-HT7 receptor: role in novel object discrimination and relation to novelty-seeking behavior. Neuroscience. 2007;149: 192-202.
8. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-65.
9. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229-32.
10. Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14:245-50.
11. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193-203.
12. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-8.
13. Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013;1-91.
14. Brown R, Taylor MJ, Geddes J. Aripiprazole alone or in combination for acute mania. Cochrane Database Syst Rev. 2013;17:12.
15. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin. 2013;29:813-25.
16. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302:381-9.
17. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, et al. Olanzapine: a basic science update. Br J Psychiatry. 1999;37:36-40.
18. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsych Dis Treat. 2012;8:155-68.
19. Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Therap Clin Risk Manag. 2013;9:319-28.
20. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-93.
21. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacotherap. 2002;36:839-51.
22. Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior risk/benefit profile to haloperidol in schizophrenia: results of a amulticentre, double-blind study. Amisulpride study Group. Eur Psychiatry. 2000;15:321-9.
23. Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005;27:103-6.
24. Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL. Correlation between scores on continuous performance test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci. 2004;58:168-72.
25. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983;3:1607-19.
26. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, et al. Single- vs multipledose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 1990;7:347-51.
27. Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2012a;8:873-88.
28. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012b;29:815-25.
29. Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013a;27:879-911.
30. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013b;30:114-26.
31. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013c;9:193-206.
32. Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10:893-903.
33. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89-93.
34. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22:1879-92.
35. Cutler A, Ball S, Stahl SM. Dosing atypical antipsychotics. CNS Spectr. 2008;13(5 Suppl 9):1-16.
36. Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, openlabel extension trial. CNS Spectr. 2013;18:43-54.
37. Daniel DG, Zimbroff D, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491-505.
38. Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17:478-84.
39. De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P, et al. Aripiprazole in acute mania and long-term treatment of bipolar disorder. A critical review by an italian working group. Clin Drug Investig. 2010;30:827-41.
40. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649-66.
41. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-22.
42. Di Lorenzo R, Brogli A. Profile of olanzapine longacting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsych Dis Treat. 2010;6:573-81.
43. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;18(2):CD001359.
44. Eap CB, Bender S, Jaquenoud SE, Cucchia G, Jonzier-Perey M, Baumann P, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214-9.
45. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70: 91-100.
46. Emsley RA. Risperidone in the treatment of firstepisode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull. 1999;25:721-9.
47. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry. 1993;38(Suppl 3):80-8.
48. Fabrazzo M, La Pia S, Monteleone P, Esposito G, Pinto A, De Simone L, et al. Is the time corse of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002;27:1050-5.
49. Fabre JR, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI. 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17:366-78.
50. Fellows L, Ahmad., Castle DJ, Dusci LJ, Bulsara MK, Ilett KF. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit. 2003;25:682-9.
51. Frampton JE. Olanzapine long-acting injection. A review of its use in the treatment of schizophrenia. Drugs. 2010;70:2289-313.
52. Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:93-100.
53. Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine D2 and 5HT2 receptor blockade and plasma drug concentration after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 1998;135:119-26.
54. Gefvert O, Lundberg T, Wieselgren I, Bergstrom M, Langstrom B, Wiesel F, et al. D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11:105-10.
55. Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8:27-36.
56. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46-53.
57. Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Rec Clin Trials. 2012;7:2-9.
58. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253-73.
59. Green MJ, Matheson SL, Sheperd A, Weickert CS, Carr VJ. Brain derived neurotrophic factor levels in schizophrenia: a systematic review with metaanalysis. Mol Psychiatry. 2011;16:960-72.
60. Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interaction for seroquel. Schizophr Res. 1997;24:198.
61. Grimm SW, Richtand NM, Winter HR, Stams KR, Reel SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Pharmacol. 2006;61:58-69.
62. Gunasekara NS, Spencer CM. Quetiapine. A review of its use in schizophrenia. CNS Drugs. 1998;9:325-40.
63. Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS drugs. 2002;16:645-52.
64. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925-35.
65. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188-94.
66. Hikaru H, Reiji Y, Yasuhisa Y, Atsuko I, Masae M, Yoshishige I, et al. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol. 2007;22:21-7.
67. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20: 389-409.
68. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetic. 1993;24:161-76.
69. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137-40.
70. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-8.
71. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry. 2000;57:553-9.
72. Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25: 81-93.
73. Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16:249-61.
74. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixeddose study. Schizophr Res. 1999;40:101-14.
75. Khan AY, Preskorn SH. Examining concentrationdependence toxicity of clozapine: role of therapeutic drug monitoring. J Psychiat Pract. 2005;11:289-301.
76. Kronig MH, Munne RA, Szymansky S, Safferman AZ, Pollack S, Cooper T, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995;152: 179-82.
77. Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, et al. Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand. 2005;111:232-43.
78. Lane HY, Guo SC, Hwang TJ, Chen YS, Cheng JJ, Lee YC, et al. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol. 2002; 22:530-2.
79. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999;20:612-27.
80. Leysen JE, Gommeren W, Eens A, Courcelles D, Stoof JC, Jansen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1998;247:661-70.
81. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in firstepisode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003; 160:1396-404.
82. Lindborg SR, Beasley C., Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003;15;119:113-23.
83. Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsych Dis Treat. 2010;6:261-7.
84. Luoni A, Rocha FF, Riva MA. Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2014;50:94-101.
85. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-87.
86. Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818-25.
87. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry. 2007;164:1411-7.
88. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008; 69:81-6.
89. Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale. 2005;31:609-15.
90. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Meibach R, et al. Absorption, metabolism, and excretion of Risperidone in humans. Drug Metab Disp. 1993;21:1134-41.
91. Marder SR, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-35.
92. Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Safety. 1996;14: 288-98.
93. Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, et al. Long term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry. 2001;16:57-63.
94. Mauri MC, Volonteri LS, Fiorentini A, Invernizzi G. Bareggi SR. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res. 2004a;66:197-8.
95. Mauri MC, Fiorentini A, Volonteri LS, Beraldo S, Dell’Osso B, Valli I, et al. Quetiapine in acute psychosis and personality disorders during hospitalization: assessment of a therapeutic range. Eur Neuropsychopharmacol. 2004b;14(S3):283-4.
96. Mauri MC, Steinhilber CPC, Marino R, Invernizzi E, Fiorentini A, Cerveri G, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20:55-60.
97. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, DeGaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics. A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007a;46: 359-88.
98. Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007b;8: 2207-13.
99. Mauri MC, Colasanti A, Rossattini M, Volonteri LS, Dragogna F, Valli A, et al. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry. 2007c;40:1-4.
100. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar disorder. Drugs. 2004;64:2709-26.
101. McGavin JK, Goa KL. Aripiprazole. CNS Drugs. 2002;16:779-88.
102. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer, HY (ed): Novel antipsychotic drugs. New York: Raven Press; 1992 (pp 1-13).
103. Meltzer HY. Mechanism of action of atypical antipsychotic drugs. In: Charney D, Coyle JT, Nemeroff C (eds): Neuropsychopharmacology: the fifth generation of progress. Philadelphia, PA: Lippincott, Williams and Wilkins; 2002 (pp 819-31).
104. Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci. 1989;238: 332-9.
105. Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49:5-13.
106. Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J Clin Pharmacol. 2005;45:620-30.
107. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry. 2005;10: 79-104.
108. Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res. 2014;261:26-30.
109. Nesvag R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114:21-6.
110. Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to Clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444-9.
111. Odou P, Levron JC, Luyckx M, Brunet C, Robert H. Risperidone drug monitoring. Clin Drug Invest. 2000;19:283-92.
112. Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson’s disease. CNS Neurosci Ther. 2011;17:58-65.
113. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit. 1999; 21:87-90.
114. Parikh V, Khan MM, Mahadik SP. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett. 2004;356: 135-9.
115. Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, et al. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet. 2011;50:471-81.
116. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280: 73-82.
117. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-5.
118. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997;17:472-7.
119. Peuskens J; Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallelgroup study versus haloperidol. Br J Psychiatry. 1995; 166:712-26.
120. Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265-73.
121. Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55:133-6.
122. Prakash C, Kamel A, Gummerus J. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Drug Metab Disp. 1997;25:863-72.
123. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet. 2005;44:1117-33.
124. Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001;50:89-93.
125. Rado JT, Janicak PG. Long-term efficacy and safety of iloperidone: an update. Neuropsychiat Dis Treat. 2014;10:409-15.
126. Riedel M, Schwarz MJ, Strassing M, Spellmann A, Muller-Arends A, Weber K, et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255:261-8.
127. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17:1-13.
128. Schatzberg AF, Nemeroff CB (eds). Essentials of clinical psychopharmacology. 3rd ed. Arlington, VA: American Psychiatric Pub.; 2013.
129. Schmidt AW, Lebel LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;;425:197-201.
130. Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42:607-18.
131. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47:27-38.
132. Seeman P, Van Tool HHM. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol Mol Pharmacol. 1995;291:59-66.
133. Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. 2011; 218:579-87.
134. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr. 2004;9(S11):6-14.
135. Small JG, Hirsch SRM, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia. A high- and low-dose double blind comparison with placebo. Arch Gen Psych. 1997;54:549-57.
136. Small JG, Kellams JJ, Kolar MC. Relationship between quetiapine dose and efficacy. Presented at the 15th European College of Neuropsychopharmacology Congress; October 5-9, 2002; Barcelona, Spain. 2002.
137. Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl). 2001;153:238-43.
138. Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74:507-15.
139. Stewart TD, Hatch A, Largay K, Sheehan JJ, Marler SV, Berman RM, et al. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: A pooled analysis. J Affect Disord. 2014;162: 20-5.
140. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Therap. 2002;24:21-37.
141. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Therap. 2010;32(SA):3-20.
142. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 1996;14:97-104.
143. Swainston HT, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715-36.
144. Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73:1533-40.
145. Weber J, Lyseng-Williamson KA, Scott LJ. Aripiprazole in major depressive disorder. CNS Drugs. 2008; 22:807-13.
146. Wilner KD, Tensfeldt TG, Baris B, Smolarek A, Turncliff RZ, Colburn WA. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol. 2000;49 (Suppl 1):15-20.
147. Winans E. Aripiprazole. Am J Health Syst Pharm. 2003;60:2437-45.
148. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48:716-21.
149. Yokoi F, Grunder G, Biziere K, Stephane M, Dogman AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology. 2002;27:248-59.
150. Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005;115:1539-47.